{"entity":{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","aka":["Apatinib"],"tldr":"Apatinib, sold as rivoceranib outside China, was the first pill of its kind approved for stomach cancer and is now the partner of camrelizumab in first-line liver cancer.","summary":"Hengrui's apatinib was approved by the CFDA in October 2014 for advanced gastric or gastro-oesophageal junction adenocarcinoma after two or more lines, the first oral VEGFR2 inhibitor approved for gastric cancer anywhere, and in December 2020 for hepatocellular carcinoma after prior systemic therapy. Combined with camrelizumab it beat sorafenib in first-line HCC (CARES-310, Lancet 2023) and was approved in China in January 2023; the same combination has drawn three complete response letters from the FDA over manufacturing inspections and trial conduct rather than efficacy. Elevar Therapeutics (HLB) holds ex-China rights.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Apatinib","links":[{"label":"Jiangsu Hengrui Pharmaceuticals","url":"https://www.hengrui.com/en/"},{"label":"CARES-310 (Lancet 2023)","url":"https://doi.org/10.1016/S0140-6736(23)00961-3"},{"label":"NMPA (National Medical Products Administration)","url":"https://www.nmpa.gov.cn"}],"tags":["china"],"related":["camrelizumab-rivoceranib","camrelizumab"],"cancers":["gastric","hcc"],"sections":[],"technologies":["kinase-inhibitors","antiangiogenic"],"targets":["vegf"],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":["vegf-angiogenesis"],"terms":[],"trials":["cares-310","nct04639180","nct05320692","nct05934331","nct04342910"],"people":[],"bottlenecks":[],"keyPapers":["paper-qin-lancet"],"journals":[],"dependsOn":[],"notes":[],"brand":"Aitan","code":"apatinib, YN968D1","modality":"Small-molecule VEGFR2 TKI","mechanism":"Selective ATP-competitive inhibitor of VEGFR2 (KDR) with weaker activity on RET, KIT and SRC; blocks tumour angiogenesis.","approvals":[{"region":"China","year":2014,"indication":"Advanced gastric or gastro-oesophageal junction adenocarcinoma after two or more lines"},{"region":"China","year":2020,"indication":"Advanced hepatocellular carcinoma after prior systemic therapy"},{"region":"China","year":2023,"indication":"First-line unresectable hepatocellular carcinoma with camrelizumab (CARES-310)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rivoceranib/","neighbours":{"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/"}],"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"pathway":[{"id":"hepatocellular-carcinoma-signalling","kind":"pathway","name":"Hepatocellular carcinoma (KEGG map)","route":"/pathways/hepatocellular-carcinoma-signalling/"},{"id":"vegf-angiogenesis","kind":"pathway","name":"VEGF angiogenesis","route":"/pathways/vegf-angiogenesis/"}],"trial":[{"id":"nct05934331","kind":"trial","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","route":"/trials/nct05934331/"},{"id":"nct05320692","kind":"trial","name":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","route":"/trials/nct05320692/"},{"id":"nct04639180","kind":"trial","name":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur","route":"/trials/nct04639180/"},{"id":"nct06475209","kind":"trial","name":"Adebrelimab + Apatinib in SCLC Maintenance Therapy","route":"/trials/nct06475209/"},{"id":"nct05192798","kind":"trial","name":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC","route":"/trials/nct05192798/"},{"id":"nct05019690","kind":"trial","name":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer","route":"/trials/nct05019690/"},{"id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/"},{"id":"nct07802184","kind":"trial","name":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC","route":"/trials/nct07802184/"},{"id":"nct06889688","kind":"trial","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","route":"/trials/nct06889688/"},{"id":"nct07773363","kind":"trial","name":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer","route":"/trials/nct07773363/"},{"id":"nct05447702","kind":"trial","name":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05447702/"},{"id":"nct04342910","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","route":"/trials/nct04342910/"}],"paper":[{"id":"paper-qin-lancet","kind":"paper","name":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","route":"/key-papers/paper-qin-lancet/"}],"person":[{"id":"sun-piaoyang","kind":"person","name":"Piaoyang Sun","route":"/people/sun-piaoyang/"},{"id":"qin-shukui","kind":"person","name":"Shukui Qin","route":"/people/qin-shukui/"}]}}